Ilhan et al. [173] report that the average serum concentration of visfatin in patients with endometrial cancer was 14.9 ng/mL compared to the control group, where the average visfatin concentration was 8.1 ng/mL. This evidence concerns the gene NAMPT and endometrial cancer.